Braveheart Bio (BRVE) American College of Cardiology 75th Annual Scientific Session presentation summary

Study background and objectives

• BHB/HRS-1893 is a selective, reversible cardiac myosin inhibitor designed for rapid action and ease of use in symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

• The study aimed to evaluate efficacy and safety of multiple dosing regimens in adults with symptomatic oHCM.

• Current CMIs require complex titration and monitoring, limiting broader adoption.

Study design and patient characteristics

• Adults with symptomatic oHCM, resting LVOT-G ≥50 mmHg (or ≥30 mmHg with Valsalva ≥50 mmHg), LVEF ≥60%, and NYHA Class II-III were enrolled.

• Three dosing regimens were tested: 20-40-60 mg BID, 40-60-80 mg BID, and 40-80-120 mg QD.

• Baseline mean age ranged from 48.4 to 54.8 years; most patients were male and on beta blockers.

Efficacy outcomes

• Rapid, deep, and reversible reductions in LVOT-G were observed across all dosing groups.

• 86% of patients in the 40-60-80 BID cohort achieved Valsalva LVOT-G <30 mmHg; 88% maintained this at week 39 in the extension period.

• Functional capacity and symptoms improved, with increases in peak VO2, KCCQ-CSS, and NYHA class improvement in most patients.

• NT-proBNP normalized in over 80% of patients, indicating improved heart failure status.